CLC bio announces acquisition of Molegro Today.

This is an excellent opportunity for us to improve the awareness and visibility of our company in america. Our objective is to put C3BS as the world leader in neuro-scientific regenerative medicine for the treating heart failure.’.. CLC bio announces acquisition of Molegro Today, CLC bio announced the acquisition of Molegro, a specialized software company concentrating on molecular docking, including prediction and analysis of protein-ligand interactions, screening of substance databases for activities against a receptor, and dedication of molecule similarity.Unlike those techniques, the brand new nanopore method will not depend on enzymes whose activity limitations the rate of which DNA sequences could be read. ‘This places us in the initial advantageous position to be able to declare that our sequencing technique is really as fast as the quickly evolving photographic technology,’ said Meller. ‘We now have the ability of reading out about 200 bases per second, which has already been considerably faster than other industrial third-generation methods. That is only the starting place for us, and we be prepared to increase this price by up to factor of four within the next year.